Nizatidine disposition in subjects with normal and impaired renal function

George R. Aronoff, Richard F. Bergstrom, Ronald J. Bopp, Rebecca S. Sloan, John T. Callaghan

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

To test the hypothesis that renal insufficiency alters nizatidine disposition, we determined the pharmacokinetics of nizatidine and its major metabolite after a single oral dose in normal volunteers and patients with various degrees of renal dysfunction, after a single intravenous dose in normal volunteers and patients with severe renal failure and during hemodialysis. After intravenous administration the elimination half-life increased from 1.5 ± 0.2 hours in normal volunteers to 6.9 ± 3.3 hours in patients with renal failure. The plasma clearance decreased from 0.59 ± 0.07 L/kg/hr in normal volunteers to 0.14 ± 0.02 L/kg/hr in patients with renal failure. Nizatidine bioavailability was nearly 100% in normal volunteers but decreased to 75% in patients with renal failure. The volume of distribution was 1.3 ± 0.1 L/kg in normal volunteers and was not different in patients with renal failure. Nizatidine protein binding was about 30% in normal and uremic plasma. The drug was not substantially removed by hemodialysis. Patients with creatinine clearances less than 50 ml/min/1.73 m2 should receive 150 mg nizatidine once each evening. Patients with creatinine clearances less than 20 ml/min/1.73 m2 should receive 150 mg nizatidine every other night.

Original languageEnglish (US)
Pages (from-to)688-695
Number of pages8
JournalClinical Pharmacology and Therapeutics
Volume43
Issue number6
DOIs
StatePublished - Jun 1988

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Nizatidine disposition in subjects with normal and impaired renal function'. Together they form a unique fingerprint.

  • Cite this